Local Compression Seroma DIminution Objective (CLODIS)

NCT ID: NCT03598712

Last Updated: 2025-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-18

Study Completion Date

2020-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the impact of local compression by chest bandage on the number of seroma punctures in patients treated by mastectomy with or without lymphadectomy. Half of the participants will have local compression by chest bandage in addition to seroma punctures while the other half will only have punctures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The most common complication induced by mastectomy is seroma formation. This seroma is a serolymphatic effusion that is created in the days following surgery. Iterative puncture is the only treatment for seroma mentioned in the literature. A retrospective study in the investigator's establishment on 1800 patients determined that a second puncture greater than 250ml is predictive of a chronicisation of punctures. The research hypothesis is that by applying local compression by chest bandaging with the Urgo® K2 kit, the "dead space" created by surgery would be removed. This would help resorb the seroma and reduce the number of punctures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Mastectomy Seroma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Phase 3 prospective, randomized, monocentric controlled study
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Compression by chest bandage urgo K2®

After the second puncture, the local compression by thoracic bandage will be put in place.

The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.

During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.

The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation.

Group Type EXPERIMENTAL

Compression by chest bandage urgo K2®

Intervention Type DEVICE

1. \- Installation of a short stretch belt (urgo K2® kit)
2. \- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).
3. \- Control of the pressure exerted by the bandage by the "KIKUHIME® Sub Bandge pressure Monitor" device

punctures

Intervention Type PROCEDURE

Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.

punctures

After the second puncture, the patient will be seen at the same frequency as in the experimental arm.

The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical.

Group Type ACTIVE_COMPARATOR

punctures

Intervention Type PROCEDURE

Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Compression by chest bandage urgo K2®

1. \- Installation of a short stretch belt (urgo K2® kit)
2. \- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).
3. \- Control of the pressure exerted by the bandage by the "KIKUHIME® Sub Bandge pressure Monitor" device

Intervention Type DEVICE

punctures

Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient followed for histologically proven breast cancer treated by total mastectomy, whether or not dissociated from the sentinel node technique, with or without axillary curing.
* Patient with a second seroma puncture with a volume greater than or equal to 250 ml.
* Neo adjuvant chemotherapy authorized.
* Absence of known metastases.
* Patient has given written consent.

Exclusion Criteria

* Mastectomy with immediate reconstruction.
* Partial mastectomy.
* Concurrent bilateral mastectomy.
* Delay in healing observed at inclusion.
* Patient under legal protection.
* Chronic respiratory failure.
* Patient with a pacemaker.
* Personality disorders and known progressive psychiatric pathology.
* Inability to submit to trial follow-up
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Francois Baclesse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

TANQUEREL Julie

Caen, , France

Site Status

Centre Françis Baclesse

Caen, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLODIS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Quilting Sutures After Mastectomy
NCT06415032 RECRUITING NA
Subclinical Lymphedema Treatment Study
NCT03292198 ACTIVE_NOT_RECRUITING NA
Therapeutic Nipple Sparing Mastectomy.
NCT02311959 COMPLETED PHASE3